

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex: 37 years Female

Specimen Collected: 20-Mar-23 14:26

Drug Profile, Screen with Rfx to Quant | Received: 23-Mar-23 14:30 | Report/Verified: 23-Mar-23 15:53

Procedure	Result	Units	Reference Interval
Creatinine, Urine	177.8	mg/dL	[20.0-400.0]
Amphetamines, Urn, Screen	Negative	ng/mL	[Cutoff 300]
Barbiturates, Urn, Screen	Negative	ng/mL	[Cutoff 200]
Benzodiazepines, Urn, Screen	Negative	ng/mL	[Cutoff 200]
Cocaine, Urn, Screen	Negative	ng/mL	[Cutoff 150]
Methadone, Urn, Screen	Negative	ng/mL	[Cutoff 150]
THC, Urn, Screen	Negative	ng/mL	[Cutoff 50]
Buprenorphine, Urn, Screen	Negative	ng/mL	[Cutoff 5]
Opiates, Urn, Screen	Negative	ng/mL	[Cutoff 300]
Oxycodone/Oxymorphone, Urn, Screen	Negative	ng/mL	[Cutoff 100]
Phencyclidine, Urn, Screen	Negative	ng/mL	[Cutoff 25]
Propoxyphene, Urn, Screen	Negative	ng/mL	[Cutoff 300]
Carisoprodol, Urn, Screen	Negative	ng/mL	[Cutoff 100]
Fentanyl, Urn, Screen	Negative	ng/mL	[Cutoff 1]
Meperidine, Urn, Screen	Negative	ng/mL	[Cutoff 200]
Tapentadol, Urn, Screen	Positive	ng/mL	[Cutoff 200]
Tramadol, Urn, Screen	Positive	ng/mL	[Cutoff 100]
Zolpidem, Urn, Screen	Negative	ng/mL	[Cutoff 20]
Ethyl Glucuronide Screen w/Rflx, Urine	Negative ⁱ¹	ng/mL	[Cutoff 500]

Screen, Urine Interpretation See Note ⁱ²

Tapentadol and Metabolite, Urn, Quant | Received: 23-Mar-23 14:30 | Report/Verified: 23-Mar-23 15:59

Procedure	Result	Units	Reference Interval
N-desmethyltapentadol, Urn, Qual	Negative		
Tapentadol glucuronide, Urn, Quant	1936	ng/mL	
Tapentadol, Urn, Quant	60 ⁱ³	ng/mL	
Tapentadol-O-sulfate, Urn, Qual	Positive		

Tramadol and Metabolite, Urn, Quant | Received: 23-Mar-23 14:30 | Report/Verified: 23-Mar-23 15:59

Procedure	Result	Units	Reference Interval
O-desmethyltramadol, Urn, Quant	>10000	ng/mL	
Tramadol, Urn, Quant	>10000 ⁱ⁴	ng/mL	

Test Information

i1: Ethyl Glucuronide Screen w/Rflx, Urine

INTERPRETIVE INFORMATION: Ethyl Glucuronide Screen with Reflex to Confirmation, Urine

Ethyl glucuronide is a direct metabolite of ethanol and can be detected up to 80 hours in urine after ethanol ingestion. The cutoff for positive by immunoassay is

* = Abnormal, # = Corrected, C = Critical, f = Result Footnote, H = High, i = Test Information, L = Low, t = Interpretive Text, @ = Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-079-900248

Report Request ID: 17731681

Printed: 23-Mar-23 16:02

Page 1 of 3

Test Information

i1: Ethyl Glucuronide Screen w/Rflx, Urine
set at 500 ng/mL. A positive result will be confirmed by liquid chromatography tandem mass spectrometry (LC-MS/MS).

i2: Screen, Urine Interpretation
INTERPRETIVE INFORMATION:

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

i3: Tapentadol, Urn, Quant
INTERPRETIVE INFORMATION: Tapentadol and Metabolite, Urine

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive Cutoff:

Tapentadol: 50 ng/mL
Tapentadol glucuronide: 100 ng/mL
Tapentadol-O-sulfate: 100 ng/mL
N-desmethyltapentadol: 100 ng/mL

For medical purposes only; not valid for forensic use.

The presence of metabolite(s) without parent drug is not uncommon and may indicate use over the prior week.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i4: Tramadol, Urn, Quant
INTERPRETIVE INFORMATION: Tramadol and Metabolite, Urine

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-079-900248

Report Request ID: 17731681

Printed: 23-Mar-23 16:02

Page 2 of 3

Test Information

i4: Tramadol, Urn, Quant

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff:

Tramadol: 25 ng/mL

o-desmethyltramadol: 25 ng/mL

For medical purposes only; not valid for forensic use.

The presence of metabolite(s) without parent drug is common and may indicate use of parent drug during the prior week.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-079-900248

Report Request ID: 17731681

Printed: 23-Mar-23 16:02

Page 3 of 3